Skip to main content

UM SOM Establishes Two Endowed Professorships Through Private Gifts and Matching State Funds

March 10, 2016

University of Maryland School of Medicine (UM SOM) Dean E. Albert Reece, MD, PhD, MBA, announced today that the School has been awarded matching funds from the Maryland Department of Business and Economic Development (DBED) as part of the Maryland E-Nnovation Initiative Fund program. The funds, when combined with private philanthropy, will enable UM SOM to establish two new endowed professorships – one in human virology and vaccine development, the other in surgical science and entrepreneurship.

The E-Nnovation program, which was created as an economic stimulus in 2014, is a special non-lapsing fund designed to help the state’s research universities recruit and retain top scientists and investigators.  Under the fund, $8.5 million will be appropriated by the governor each year from fiscal years 2016 through 2021.

This year, UM SOM secured private donations of nearly $2 million, qualifying the institution for matching state funds. As part of its goal to attract top faculty and foster the development of new technologies and therapies, the School requested that the funds be used to establish the two endowed professorships.

“Endowed professorships provide our outstanding faculty members with the critical resources they need to sustain and expand the promising research they endeavor to carry out, while at the same time enabling them to launch new initiatives to educate and train future physicians, said Dean Reece, who is also Vice President, Medical Affairs at the University of Maryland and the John Z. and Akiko K. Bowers Distinguished Professor. “Professorships are an exceptionally effective tool in retaining and recruiting the best and the brightest.”The first endowed professorship, established with an anonymous gift, will be the Robert C. Gallo Distinguished Professorship, named for Robert C. Gallo, MD, who pioneered the field of human retrovirology, and has made several scientific breakthroughs, including the co-discovery of HIV as the cause of AIDS. With this professorship, the E-Nnovations matching funds program strengthens the school’s research and development capabilities as a leader in vaccine development bringing life-saving treatments to patients around the globe.

“Ensuring that we can continue our research competitiveness by supporting new discoveries and vital care and treatment protocols in the areas of HIV/AIDS and other virally-linked diseases, as well as vaccine development, is a vital part of the School's Research Endowment Plan,” said Dr. Gallo, who is also the Homer & Martha Gudelsky Distinguished Professor of Medicine, and Director of UM SOM’s Institute of Human Virology (IHV). “In addition, the generous donations and matching funds provided through the E-Nnovation program will help IHV attract the best and the brightest medical virologists from around the world.”  

UM SOM will also use state matching funds to create an Endowed Distinguished Professorship in Entrepreneurial Surgical Science, established by a group of donors, including Thomas and Alice-Marie Hales, Hamish and Christine Osborne, The Peter and Georgia Angelos Foundation, and The Abell Foundation. The goal of the professorship is to seed a unique program that quickens the pace of developing feasible bioengineered solutions, and to increase creation of innovative medical technology and commercialization to help critically-ill people. The endowment will leverage the recruitment of a senior biomedical engineer to become the Endowed Professor in Entrepreneurial Surgical Science in the UM SOM Department of Surgery. 

“This professorship is an important part of the Department of Surgery’s plan to develop innovative surgical research programs that are ideally positioned for investment, translation and commercialization,” said Stephen T. Bartlett, MD, who is the Peter Angelos Distinguished Professor and Chairman of the Department of Surgery, as well as Executive Vice President and Surgeon-in-Chief of the University of Maryland Medical System.  

“Discoveries in critical fields including bio-designed organs, transplant tolerance, xenotransplantation, stem cell therapy and pleural and peritoneal cancers are waiting to be transformed into biomedical innovation that will revolutionize patient retreatment and improve patient outcomes.”

Ultimately, the goal is to replicate other successful startups funded by the Maryland Technology Development Corp. (TEDCO) and led by UM SOM surgeons. The creation of  Harpoon Medical, Inc., for example, co-founded in 2013 by James Gammie, MD, Professor of Surgery and Chief of the Division of Cardiac Surgery.  Harpoon’s licensed technology centers on an image-guided cardiac surgical tool inserted via a small incision between the ribs. Surgery and Executive Director of the UM SOM Program in Lung Healing, developed the first wearable “out-of-hospital “artificial lung system. UM Ventures and Breethe, Inc. announced in last year that Breethe, an early-stage, Baltimore-based medical device company, had obtained exclusive rights to University of Maryland, Baltimore intellectual property for the development of a wearable, portable blood pump oxygenator that will function as an artificial lung system for patients suffering from respiratory failure and cardiopulmonary collapse. 

The artificial lung will be the very first device in the field and will be tested first in humans at the University of Maryland Medical Center by UM SOM investigators. 

According to Brian J. DeFilippis, UM SOM Associate Dean for Development, the endowed professorships further enhance the school’s efforts to grow its research portfolio, provide a positive impact on the City of Baltimore and the State of Maryland, and engage prospective donors with an ideal opportunity for philanthropy. 

“This program presents a unique and outstanding benefit to our donors by offering the potential to magnify the impact of their philanthropy, to advance science and medicine and to propel the School of Medicine forward as a research powerhouse, said Mr. DeFilippis. “It is imperative that we capitalize on this incentive and grow the number of endowed professorships for our medical school.” 

About the University of Maryland School of Medicine 

The University of Maryland School of Maryland, chartered in 1807 as the first public medical school in the United States, continues today as a leader in accelerating innovation and discovery in medicine. The School of Medicine is the founding school of the University of Maryland, and is an integral part of the 12-campus University System of Maryland. Located on the University of Maryland’s Baltimore campus, the School of Medicine works closely with the University of Maryland Medical Center and Medical System to provide a research-intensive, academic and clinically based education. With 43 academic departments, centers and institutes and a faculty of more than 3,000 physicians and research scientists, plus more than $400 million in extramural funding, the School is regarded as one of the leading biomedical research institutions in the U.S., with top-tier faculty and programs in vaccine development, cancer, brain science, surgery and transplantation, trauma and emergency medicine, and human genomics, among other centers of excellence. The School is not only concerned with the health of the citizens of Maryland and the U.S., but also has a global presence, with research and treatment facilities in more than 30 countries around the world.


Office of Public Affairs
655 West Baltimore Street
Bressler Research Building 14-002
Baltimore, Maryland 21201-1559

Contact Media Relations
(410) 706-5260

Related stories

    Tuesday, December 04, 2018

    Institute of Human Virology Researchers Discover That a Bacterial Protein Promotes Cancer

    The Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) announced today the discovery that DnaK, a protein of the bacterium mycoplasma, interferes with the mycoplasma-infected cell’s ability to respond to and repair DNA damage, a known origin of cancer.

    Monday, December 03, 2018

    Institute of Human Virology Names Dr. Man Charurat as Director of the Center for International Health, Education, and Biosecurity

    The Institute of Human Virology (IHV) at the University of Maryland School of Medicine today announced the appointment of Man E. Charurat, PhD, MHS, Professor of Medicine and Director of the Division of Epidemiology and Prevention at the IHV as the Director of IHV’s Center for International Health, Education, and Biosecurity (CIHEB). Dr. Charurat will replace Deus Bazira, DrPH, MPH, MBA. The announcement was made by Robert C. Gallo, MD, The Homer & Martha Gudelsky Distinguished Professor in Medicine, Co-Founder and Director of the IHV, and Co-Founder and Director of the Global Virus Network (GVN).

    Tuesday, October 23, 2018

    Institute of Human Virology Hosts 20th Annual International Meeting of Top Medical Virus Researchers in Baltimore, Maryland

    The Institute of Human Virology (IHV) at the University of Maryland School of Medicine yesterday commenced IHV’s 20th Annual International Meeting, to be held through Thursday, October, 25 at the Four Seasons Hotel in Baltimore, Maryland. This year, among other viral and cancer related topics, the meeting is holding special sessions on the 40th anniversary of the first human retrovirus, Human T cell Leukemia Virus (HTLV), and the 15th anniversary of the President’s Emergency Plan for AIDS Relief (PEPFAR). IHV’s Annual International Meeting attracts hundreds of elite scientists who descend upon Baltimore to share ideas and inspire medical virus research collaborations.

    Wednesday, September 19, 2018

    Institute of Human Virology (IHV) Awarded $12M to Combat Opioid Epidemic Through Clinical Research Trials

    The Institute of Human Virology (IHV) at the University of Maryland School of Medicine will lead a $12 million dollar project to improve the morbidity and mortality of people with opioid use disorder (OUD). Utilizing a novel compound, IHV researches will implement a series of investigations, entitled SEARCH, to evaluate the underlying mechanisms of craving reduction as a strategy to prevent opioid misuse, dependence, and relapse. The grant is awarded through the National Institutes of Health’s (NIH) Helping to End Addiction Long-term (HEAL) Initiative, made possible through groundbreaking funding from the U.S. Congress.

    Tuesday, December 12, 2017

    A Statement from the Leadership of the Institute of Human Virology on the Passing of Stewart Greenebaum

    The Institute of Human Virology (IHV) at the University of Maryland School of Medicine mourns the passing of Stewart Greenebaum, a lifelong Baltimore resident, former president of Greenebaum and Rose Associates, and past chairman of the IHV Board of Advisors, as well as a guiding force in the establishment of the IHV at the University of Maryland, Baltimore.

    Wednesday, November 29, 2017

    To Mark World AIDS Day, Institute of Human Virology Releases Video on Dr. Robert Gallo

    The Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) released a video on Dr. Robert Gallo, a trailblazer in HIV research, in advance of World AIDS Day, December 1. While many know Dr. Gallo for his pioneering work in AIDS research, the short video focuses on Dr. Gallo’s life and legacy in its entirety, including his pioneering discovery of human retroviruses.

    Tuesday, October 25, 2016

    "A Call to End HIV/AIDS in America" IHV Director Dr. Robert Gallo's Op-Ed in the Huffington Post

    As the new Administration is presented with great challenges facing the United States, one will be a longtime foe, the U.S. HIV/AIDS epidemic. Since President Barack Obama was elected in 2008, I have publicly called on our country’s leaders to utilize the largest global health initiative in history - the President’s Emergency Plan for AIDS Relief (PEPFAR) - as a model to address the U.S. epidemic.

    Monday, August 22, 2016

    Institute of Human Virology (IHV) Awarded $14.4M for HIV Vaccine Research

    The Institute of Human Virology (IHV) announced a $14.4M grant from NIAID to advance HIV vaccine research to solve a major challenge: produce long-lasting antibodies to protect against HIV infection.

    Tuesday, September 29, 2015

    Institute of Human Virology Hosts International Meeting of Prominent AIDS Researchers

    The Institute of Human Virology (IHV) at the University of Maryland School of Medicine is hosting IHV’s 17th Annual International Meeting Sunday, September 27 through Wednesday, September 30 at the Baltimore Marriott Waterfront Hotel in Baltimore, Maryland.